Our worldwide research and development network connects Japan, the United States, Europe, India and East Asian countries. Our R&D function, including Daiichi Sankyo Novare and Asubio Pharma, is primarily based at four sites in Japan. They collaborate with Daiichi Sankyo Group companies in the US, Europe and Asia, on everything from drug discovery to development and pharmaceutical technology research. In clinical trials, this wealth of expertise from around the world is shared to carry out global decision-making.
In the United States, Daiichi Sankyo Pharma Development (DSPD), an unincorporated division of Daiichi Sankyo, Inc., oversees global clinical trials from Edison, New Jersey. What’s more, other bases in Asia, such as Daiichi Sankyo Korea, Daiichi Sankyo Taiwan, Daiichi Sankyo (China), and Daiichi Sankyo India Development, contribute to the continued introduction of new products onto the market.
Concerning research, in Germany the Tissue and Cell Research Center Munich carries out pharmacokinetic studies and toxicity tests.
Additionally, the Daiichi Sankyo Life Science Research Center in India (RCI) is carrying out valuable research into inflammatory and infectious diseases.
Finally, Plexxikon Inc., based in Berkley, California, is advancing R&D for oncology, from research to early-stage development.